US Healthcare Reform to Benefit Indian Generics Industry

The recent healthcare reform in the US will drive the growth in demand for low-cost Indian generics drugs, says RNCOS in its new research report.

Online PR News – 18-June-2010 – – The healthcare reform was a milestone in the history of US generic drugs industry, and this will benefit the US generic drugs industry in long-term growth scenario. The US government has now shifted its focus on generic drugs to minimize its healthcare spending and thus, opportunities are being created for generics manufacturers. The generic drugs manufactured in the US are costly due to high cost of manufacturing and therefore demand for imported drugs is increasing. As majority of these drugs are imported from India, the increasing demand in the US is benefitting the Indian generics manufacturers. As per our new research on the sector called “Booming Generics Drug Market in India”, the Indian generics market is forecasted to grow at a CAGR of around 17% between FY 2011 and FY 2013.

According to the report, India has emerged strongly as a major generics manufacturer in the world. The Indian generics industry has witnessed a lot of investments in last few years and these investments will help the industry in expanding its manufacturing capabilities. We have also found that India exports a major part of its production to the developed countries and our research provides reliable statistics in this regard.

The report highlights the fact that the industry is witnessing an increase in number of marketing alliances and acquisitions, and it includes the details of such deals. Besides, the business information of the key industry players has also been covered in the report, which will give an additional advantage to the clients.

“Booming Generics Drug Market in India” is the outcome of our extensive research and thorough analysis on the burgeoning generics industry. The report also discusses the market structure, current and past market performance and factors critical to the success of the generic drugs market in India. It also discusses the role that regulatory factors play in the overall growth of the market, which will guide clients to make intelligent investment decisions.

For FREE SAMPLE of this report visit: http://www.rncos.com/Report/IM256.htm

Check DISCOUNTED REPORTS on: http://www.rncos.com

About RNCOS:

RNCOS specializes in Industry intelligence and creative solutions for contemporary business segments. Our professionals study and analyze the industry and its various components, with comprehensive study of the changing market behavior. Our accuracy and data precision proves beneficial in terms of pricing and time management that assist the consultants in meeting their objectives in a cost-effective and timely manner.

Bookmarkse-mailGoogledel.icio.usStumbleUponSlashdotFurlDiggTechnoratiYahooMyWebBlinkListSpurlRawSugarWists
 
 
Contact Information
Shushmul Maheshwari
B 129 Sector 6 Noida 201301
Noida Uttar Pradesh, 201301

91-120-4224-700